[January 07, 2014]

Medgenics Issues Stock Options and Restricted Shares to Non-Executive Directors

Medgenics, Inc. (NYSE MKT: MDGN and AIM: MEDU, MEDG) (the Company), the developer of Biopump^(TM) a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, announces that on January 2, 2014, the Company granted options to subscribe for 15,000 shares of the Company's common stock, par value US$0.0001 ("Common Shares") ("Options") and made a restricted share award of 7,000 Common Shares ("Restricted Shares") to each of Sol Barer, Isaac Blech, Alastair Clemow, Wilbur "Bill" Gantz, Joseph Grano, Jr., Joel Kanter, Stephen McMurray, and Andrew Pearlman, all non-executive directors of the Company, as part of their remuneration for the year.

Fifty percet of these Restricted Shares were vested on January 3, 2014 and the remaining fifty percent will be vested one year from the date awarded, January 2, 2014 (the "Reference Date"). All of the Options are for a term of 10 years commencing on the Reference Date, vest in equal instalments on each of the first three anniversaries of the Reference Date and have an exercise price of US$6.50 or, based on an exchange rate of £1=US$1.65, 394 pence per Common Share, being the MDGN closing price on the Reference Date as reported on NYSE MKT.

These awards of Restricted Shares and Options were made pursuant to the terms of the Company's 2006 Stock Incentive Plan (as amended, the "2006 Stock Plan") previously approved by the Company's stockholders and in accordance with the Board approved non-executive director compensation program adopted on March 22, 2010 and amended on December 9, 2011 and October 16, 2012, which provides for each non-executive director: annual grants of options to purchase 15,000 Common Shares and awards of 7,000 Restricted Shares; an annual cash retainer fee of $15,000; and meeting attendance fees ranging from $1,000 to $2,500 per meeting, depending on the location and type of meeting. In addition, committee chairmen are entitled to an annual cash fee of $5,000.

This announcement is being made pursuant to the London Stock Exchange's AIM Rules for Companies admitted to trading on the AIM market.

[ Back To TMCnet.com's Homepage ]